Literature DB >> 27146492

Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.

Kristen J Wells1,2,3, Tonya M Pan4,5, Coralia Vázquez-Otero6, Danielle Ung6, Amy E Ustjanauskas4,5, Dariana Muñoz7, Christine Laronga6,8, Richard G Roetzheim6,8, Marissa Goldenstein9, Claudia Carrizosa7, Sumayah Nuhaily10, Kenneth Johnson11, Marilyn Norton11, Elizabeth Sims12, Gwendolyn P Quinn6,8.   

Abstract

PURPOSE: To evaluate the barriers and facilitators to taking anti-hormonal medications among medically and historically underserved breast cancer survivors within the first 5 years post chemotherapy, radiation, and/or surgery.
METHODS: The current study was framed within the National Institutes of Health Centers for Population Health and Health Disparities Model (NIHCPHHD Model). Twenty-five historically or medically underserved breast cancer survivors participated in an in-depth interview, in either English or Spanish. Interviews were audio recorded and transcribed verbatim. Interview data were analyzed using content analysis.
RESULTS: Anti-hormonal medication adherence was facilitated in several ways, including establishing a routine of medication taking, leaving the medicine in a visible or easily accessible place, taking the medication with other medications, reducing the cost of medicine, using a pillbox, understanding the negative consequences of lack of adherence, and having positive interactions with physicians. Side effects were the most commonly mentioned barrier to medication adherence.
CONCLUSIONS: Similar to other research, this qualitative study of medically and historically underserved breast cancer survivors in the USA found that side effects are the most frequently endorsed barrier to anti-hormonal medication adherence. Conversely, there were a number of facilitators of correct and consistent anti-hormonal medication use. The management of side effects is critically important to increase adherence to anti-hormonal medications. Health care providers, support providers, and caregivers can encourage breast cancer survivors to better adhere to anti-hormonal medications using a number of approaches that have been successful for other women.

Entities:  

Keywords:  Breast cancer; Breast neoplasms; Cancer; Medication adherence; Oncology

Mesh:

Substances:

Year:  2016        PMID: 27146492      PMCID: PMC4995114          DOI: 10.1007/s00520-016-3229-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  22 in total

Review 1.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Authors:  Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

2.  A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians.

Authors:  Laetitia Huiart; Cyril Ferdynus; Roch Giorgi
Journal:  Breast Cancer Res Treat       Date:  2013-02-12       Impact factor: 4.872

3.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

Review 4.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

Review 5.  Adjuvant endocrine therapy for breast cancer.

Authors:  Ruta D Rao; Melody A Cobleigh
Journal:  Oncology (Williston Park)       Date:  2012-06       Impact factor: 2.990

Review 6.  Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research.

Authors:  Julia R Van Liew; Alan J Christensen; Janet S de Moor
Journal:  J Cancer Surviv       Date:  2014-07-02       Impact factor: 4.442

Review 7.  Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.

Authors:  Peyman Hadji
Journal:  Crit Rev Oncol Hematol       Date:  2009-03-18       Impact factor: 6.312

8.  Adherence to tamoxifen over the five-year course.

Authors:  Timothy L Lash; Matthew P Fox; Jennifer L Westrup; Aliza K Fink; Rebecca A Silliman
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

Review 9.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

10.  A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.

Authors:  Alison Harrow; Ruth Dryden; Colin McCowan; Andrew Radley; Mark Parsons; Alastair M Thompson; Mary Wells
Journal:  BMJ Open       Date:  2014-06-12       Impact factor: 2.692

View more
  13 in total

1.  It's not an easy fix: Adherence to adjuvant endocrine therapy after breast cancer.

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard
Journal:  Can Oncol Nurs J       Date:  2021-05-01

2.  Patient-provider communication and hormonal therapy side effects in breast cancer survivors.

Authors:  Jenny J Lin; Jennifer Chao; Nina A Bickell; Juan P Wisnivesky
Journal:  Women Health       Date:  2016-09-12

3. 

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard
Journal:  Can Oncol Nurs J       Date:  2021-05-01

4.  Leveraging Mobile Sensing to Understand and Develop Intervention Strategies to Improve Medication Adherence.

Authors:  Anna N Baglione; Jiaqi Gong; Mehdi Boukhechba; Kristen J Wells; Laura E Barnes
Journal:  IEEE Pervasive Comput       Date:  2020-06-26       Impact factor: 3.175

5.  Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors.

Authors:  Jennifer C Spencer; Bryce B Reeve; Melissa A Troester; Stephanie B Wheeler
Journal:  Psychooncology       Date:  2020-02-11       Impact factor: 3.894

6.  A Social Cognitive Theory-based Framework for Monitoring Medication Adherence Applied to Endocrine Therapy in Breast Cancer Survivors.

Authors:  Mehdi Boukhechba; Sonia Baee; Alicia L Nobles; Jiaqi Gong; Kristen Wells; Laura E Barnes
Journal:  IEEE EMBS Int Conf Biomed Health Inform       Date:  2018-04-09

7.  The psychosocial needs of underserved breast cancer survivors and perspectives of their clinicians and support providers.

Authors:  Kristen J Wells; Julia H Drizin; Amy E Ustjanauskas; Coralia Vázquez-Otero; Tonya M Pan-Weisz; Danielle Ung; Claudia Carrizosa; Christine Laronga; Richard G Roetzheim; Kenneth Johnson; Marilyn Norton; Rosa Cobian Aguilar; Gwendolyn P Quinn
Journal:  Support Care Cancer       Date:  2021-07-07       Impact factor: 3.603

8.  Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.

Authors:  Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell
Journal:  Curr Oncol       Date:  2021-07-05       Impact factor: 3.677

9.  Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.

Authors:  Yiqi Pan; Sarah R Heisig; Pia von Blanckenburg; Ute-Susann Albert; Peyman Hadji; Winfried Rief; Yvonne Nestoriuc
Journal:  Breast Cancer Res Treat       Date:  2018-01-12       Impact factor: 4.872

10.  Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard; Stephen K Chia; Carolyn C Gotay
Journal:  BMC Cancer       Date:  2018-07-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.